Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study

BACKGROUND: Outcomes after metastasectomy for metastatic colorectal cancer (mCRC) vary with RAS and BRAF mutational status, but their effects on resectability and conversion rates have not been extensively studied. METHODS: This substudy of the prospective RAXO trial included 906 patients recruited...

Descripción completa

Detalles Bibliográficos
Autores principales: Uutela, Aki, Osterlund, Emerik, Halonen, Päivi, Kallio, Raija, Ålgars, Annika, Salminen, Tapio, Lamminmäki, Annamarja, Soveri, Leena-Maija, Ristamäki, Raija, Lehtomäki, Kaisa, Stedt, Hanna, Heervä, Eetu, Muhonen, Timo, Kononen, Juha, Nordin, Arno, Ovissi, Ali, Kytölä, Soili, Keinänen, Mauri, Sundström, Jari, Nieminen, Lasse, Mäkinen, Markus J., Kuopio, Teijo, Ristimäki, Ari, Isoniemi, Helena, Osterlund, Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381729/
https://www.ncbi.nlm.nih.gov/pubmed/35610367
http://dx.doi.org/10.1038/s41416-022-01858-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381729/
https://www.ncbi.nlm.nih.gov/pubmed/35610367
http://dx.doi.org/10.1038/s41416-022-01858-8

Ejemplares similares